To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
![]() Fahn Tolosa Marin Tremor Rating Scale Drawings Download Citation CopyMarin Download full-text PDF Download full-text PDF Read full-text Download full-text PDF Download full-text PDF Read full-text Download citation Copy link Link copied Read full-text Download citation Copy link Link copied Citations (341) Discover the worlds research 20 million members 135 million publications 700k research projects Join for free Public Full-texts 2 tremor scale.pdf Content available from Eduard Tolosa: tremor scale.pdf tremor scale.pdf Content uploaded by Eduard Tolosa Author content All content in this area was uploaded by Eduard Tolosa on Nov 21, 2016 Content may be subject to copyright.
Fahn Tolosa Marin Tremor Rating Scale Drawings Upgrade Your BrowserThroughout the study, greater improvements in Fahn-Tolosa-Marin (FTM) tremor and Part B motor performance scores 19 were observed with incobotulinumtoxinA treatment versus placebo. There was a somewhat greater improvement from baseline in FTM tremor score in the incobotulinumtoxinA group versus placebo at Weeks 4 and 8, but the difference between the treatment groups was statistically significant favoring incobotulinumtoxinA at Week 8 only, when looking at the 95 confidence intervals.. This trial was a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter, exploratory study in patients with upper-limb ET (NCT02207946). Eligible patients were adults with a first onset of ET 6 months before screening and with stability of symptoms over 4 weeks; whose diagnosis of definite ET was otherwise in accordance with the Tremor Investigation Group criteria applicable at the time 23 (bilateral postural tremor withwithout kinetic tremor, involving hands and forearms, that was visible and persistent); moderate-to-marked upper-limb postural andor kinetic tremor at wrist level (FTM Part C, items 1718 19 20212223 in the limb to be treated, with a rating of 2 in at least two categories; visible tremor at wrist level in at least one of the four positionstasks used in kinematic assessment; tremor deemed by the investigator to require treatment with a total dose of 30-200 U incobotulinumtoxinA for up to 3 joints (wrist joint mandatory; shoulder and elbow joints optional); and receiving concomitant anti-tremor medication, if any, at a stable dose (4 weeks before screening and until the study end). Principal exclusion criteria are listed in the supplementary materials... No primary efficacy variables were defined in this exploratory study. Secondary efficacy variables included change from baseline to Week 4 in: maximum angular tremor amplitude of the wrist of the injected limb; maximum log-transformed accelerometric tremor amplitude at hand level of the injected limb; FTM tremor score in the injected limb 19; FTM motor performance score 19; and physicians and patients GICS score at Week 4. Changes from baseline to later time points from Weeks 8-24 were assessed every 4 weeks as further efficacy variables.. Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study Article Full-text available Dec 2020 Mandar Jog Jack Lee Astrid Scheschonka David M Simpson In this first, double-blind, randomized, placebo-controlled exploratory trial, we evaluate the efficacy and safety of incobotulinumtoxinA and feasibility of using kinematic tremor assessment to aid in the planning of muscle selection in a multicenter setting. Reproducibility of the planning technology to other clinical sites was explored. ![]() A tremor kinematic analytics investigational device was used to define a customized muscle set for injection, related to the pattern of the wrist, forearm, elbow, and shoulder tremor for each patient, and the incobotulinumtoxinA dose per muscle (total 200 U). FahnTolosaMarin (FTM) Part B motor performance score, Global Impression of Change Scale (GICS), and kinematic analysis-based efficacy evaluations were assessed. Thirty patients were randomized (incobotulinumtoxinA, n 19; placebo, n 11). FTM motor performance scores showed greater improvement with incobotulinumtoxinA versus placebo at Week 4 (p 0.003) and Week 8 (p 0.031). The physician-rated GICS score indicated improvement with incobotulinumtoxinA versus placebo at Week 4 (p View Show abstract. These items are scored with integer numbers from 0 (no tremor), up to 4 (tremor amplitude 2 cm). For more details about the FTM scoring system, we refer the reader to the original publication (Fahn et al., 1993)... In the final phase of the experimental sessions, the clinical efficacy of the aDBS strategies was compared to cDBS and DBS off, using parts A and B of the FTM scale (Fahn et al., 1993). The FTM tests were captured on camera and the videos were evaluated offline by two blinded clinical experts.. A pilot study on data-driven adaptive deep brain stimulation in chronically implanted essential tremor patients world Article Full-text available Nov 2020 FRONT HUM NEUROSCI Sebastin Castao Candamil Benjamin Ferleger Andrew Haddock Michael Tangermann Deep brain stimulation (DBS) is an established therapy for Parkinsons disease (PD) and essential-tremor (ET). In adaptive DBS (aDBS) systems, online tuning of stimulation parameters as a function of neural signals may improve treatment efficacy and reduce side-effects. State-of-the-art aDBS systems use symptom surrogates derived from neural signalsso-called neural markers (NMs)defined on the patient-group level, and control strategies assuming stationarity of symptoms and NMs. We aim at improving these aDBS systems with (1) a data-driven approach for identifying patient- and session-specific NMs and (2) a control strategy coping with short-term non-stationary dynamics. The two building blocks are implemented as follows: (1) The data-driven NMs are based on a machine learning model estimating tremor intensity from electrocorticographic signals. The control strategy accounts for local variability of tremor statistics. Our study with three chronically implanted ET patients amounted to five online sessions. Tremor quantified from accelerometer data shows that symptom suppression is at least equivalent to that of a continuous DBS strategy in 3 out-of 4 online tests, while considerably reducing net stimulation (at least 24). In the remaining online test, symptom suppression was not significantly different from either the continuous strategy or the no treatment condition. It is the first aDBS system based on (1) a machine learning model to identify session-specific NMs, and (2) a control strategy coping with short-term non-stationary dynamics. We show the suitability of our aDBS approach for ET, which opens the door to its further study in a larger patient population. A similar version of this test is widely used for the detection of Parkinsons disease and movement disorders 30. Test 6 -Drawing Test: the goal of this test is to colour the tree in the best way possible.. Child-Computer Interaction: Recent Works, New Dataset, and Age Detection Preprint Full-text available Feb 2021 Ruben Tolosana Juan Carlos Ruiz-Garcia Ruben Vera-Rodriguez Julian Fierrez We overview recent research in Child-Computer Interaction and describe our framework ChildCI intended for: i) generating a better understanding of the cognitive and neuromotor development of children while interacting with mobile devices, and ii) enabling new applications in e-learning and e-health, among others.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |